Study guide

Section 4.1: Rheumatologic & Autoimmune MSK Conditions (RA, Lupus, Gout, OA)

NCCPA PANCE Physician Assistant Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Cardiovascular System

1.1 Hypertension (Essential & Secondary) 1.2 Coronary Artery Disease & Myocardial Infarction 1.3 Heart Failure & Cardiomyopathy 1.4 Cardiac Arrhythmias & Conduction Disorders 1.5 Valvular Heart Disease 1.6 Vascular Diseases (Aortic Aneurysm, PAD, DVT) 1.7 Congenital Heart Disease (ASD, VSD, PDA, Coarctation, Tetralogy of Fallot)

2 Chapter 2: Pulmonary System

Section 2.1: Asthma & Bronchospastic Disease Section 2.2: Chronic Obstructive Pulmonary Disease (COPD) Section 2.3: Infectious Pulmonary Disorders (Pneumonia & Tuberculosis) Section 2.4: Restrictive, Vascular & Neoplastic Pulmonary Conditions

3 Chapter 3: Gastrointestinal/Nutrition

3.1 Esophageal & Gastric Disorders (GERD, PUD) 3.2 Hepatic, Biliary & Pancreatic Disorders 3.3 Small & Large Bowel Disorders (IBD, Diverticulitis, Obstruction) 3.4 Colorectal Neoplasms & Nutritional Deficiencies

4 Chapter 4: Musculoskeletal System

Section 4.1: Rheumatologic & Autoimmune MSK Conditions (RA, Lupus, Gout, OA) Section 4.2: Infectious & Inflammatory MSK Disorders (Osteomyelitis, Septic Arthritis) Section 4.3: Bone & Joint Disorders (Fractures, Osteoporosis, Fibromyalgia) Section 4.4: Spine and Soft Tissue Pathology (Low Back Pain, Tendonitis)

5 Chapter 5: Neurologic System

Section 5.1: Cerebrovascular Disease (Stroke, TIA) Section 5.2: Seizure Disorders & Epilepsy Section 5.3: Demyelinating & Neurodegenerative Diseases Section 5.4: Headache Syndromes & Cranial Nerve Disorders

6 Chapter 6: Psychiatry/Behavioral Science

Section 6.1: Depressive and Bipolar Disorders Section 6.2: Anxiety, Trauma-Related, and Obsessive-Compulsive Disorders Section 6.3: Schizophrenia and Psychotic Disorders Section 6.4: Eating, Substance Use, and Personality Disorders

7 Chapter 7: Infectious Diseases

7.1 Viral Infections (HIV, EBV, Influenza) 7.2 Bacterial & Spirochetal Infections (Sepsis, Meningitis) 7.3 Fungal & Parasitic Infections 7.4 Tick-Borne Diseases (Lyme, Rocky Mountain Spotted Fever)

8 Chapter 8: Reproductive System

8.1 Obstetrics: Normal Pregnancy & Prenatal Care 8.2 Obstetrics: Pregnancy Complications 8.3 Gynecology: Menstruation, Menopause, PCOS, and Vaginal Infections

9 Chapter 9: Endocrine System

Section 9.1: Diabetes Mellitus & Acute Complications Section 9.2: Thyroid Disorders & Goiter Section 9.3: Adrenal & Pituitary Disorders

10 Chapter 10: Eyes, Ears, Nose, and Throat

Section 10.1: Ophthalmic Disorders (Glaucoma, Conjunctivitis, Cataracts) Section 10.2: Otic Disorders (Otitis Media/Externa, Vertigo, Labyrinthitis) Section 10.3: Nose, Sinus, and Throat Complaints (Sinusitis, Pharyngitis, Epiglottitis)

11 Chapter 11: Professional Practice

11.1 Bioethics & Legal Standards (Informed Consent, Autonomy, HIPAA) 11.2 Patient Safety, Quality Improvement, and Communication 11.3 Evidence-Based Medicine & Clinical Practice Guidelines

12 Chapter 12: Hematologic System

Section 12.1: Anemias (Microcytic, Macrocytic, Hemolytic/Sickle Cell) Section 12.2: Coagulation and Bleeding Disorders (ITP, TTP, Hemophilia, vWD) Section 12.3: Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)

13 Chapter 13: Renal System

13.1 Acute Kidney Injury (AKI) & Chronic Kidney Disease (CKD) 13.2 Acid-Base and Electrolyte Disorders 13.3 Glomerular & Tubulointerstitial Diseases

14 Chapter 14: Dermatologic System

Section 14.1: Inflammatory & Autoimmune Skin Conditions Section 14.2: Infectious Skin Conditions Section 14.3: Skin Neoplasms & Burn Management

15 Chapter 15: Genitourinary System

Section 15.1: Male Genitourinary Disorders (BPH, Prostate Cancer, Testicular Torsion, ED) Section 15.2: Urinary Incontinence, Nephrolithiasis, and GU Trauma

Section 4.1: Rheumatologic & Autoimmune MSK Conditions (RA, Lupus, Gout, OA)

Key Takeaways Explain This Topic AI

Rheumatoid arthritis (RA) is characterized by symmetric polyarthritis sparing the DIP joints, morning stiffness > 1 hour, and high-specificity anti-CCP antibodies.

Systemic Lupus Erythematosus (SLE) presents with multisystem symptoms and is screened using ANA, with anti-dsDNA and anti-Smith providing high diagnostic specificity.

Gout flares are diagnosed via needle-shaped, negatively birefringent monosodium urate crystals, managed acutely with NSAIDs, colchicine, or steroids, and chronically with allopurinol.

Osteoarthritis (OA) is a degenerative joint disease characterized by asymmetric joint space narrowing, osteophytes, morning stiffness < 30 minutes, and DIP/PIP bony nodes.

Urate-lowering therapy with allopurinol requires HLA-B*5801 screening in patients of Asian or African descent to prevent severe hypersensitivity syndrome.

Last updated: July 2026

Rheumatologic & Autoimmune MSK Conditions

PANCE High-Yield Focus: Rheumatologic and autoimmune conditions represent highly tested topics on the PANCE. Key areas of focus include distinguishing inflammatory arthropathies (RA, SLE) from degenerative joint diseases (OA), interpreting specific autoantibody panels (anti-dsDNA, anti-CCP), analyzing synovial fluid crystals (needle-shaped vs. rhomboid-shaped), and knowing critical medication safety profiles (e.g., DMARD screening and HLA-B*5801 testing).

  • Pathophysiology and Clinical Comparison
  • Rheumatoid Arthritis (RA)

Rheumatoid arthritis is a chronic, systemic autoimmune inflammatory disease characterized by symmetric polyarthritis. It is driven by an autoimmune attack against the synovial membrane. T-helper cells release proinflammatory cytokines (such as tumor necrosis factor [TNF]-alpha, interleukin [IL]-1, and IL-6) that activate macrophages and synovial fibroblasts. This leads to marked hyperplasia of the synovium, forming a hypertrophic, vascularized tissue called a pannus . The pannus invades and destroys the adjacent articular cartilage and subchondral bone, mediated by osteoclast activation and collagenase release, leading to joint space narrowing, marginal bone erosions, and joint deformity.

Systemic Lupus Erythematosus (SLE)

Systemic lupus erythematosus is a multi-system autoimmune disease driven by a type III (immune complex) and type II (antibody-mediated) hypersensitivity reaction. Autoantibodies target nuclear antigens (antinuclear antibodies, or ANA), leading to the formation of immune complexes that deposit in various organs, including the skin, joints, kidneys, and blood vessels. This deposition activates the complement cascade, triggering inflammation, tissue damage, and vasculitis.

Gout

Gout is an inflammatory arthritis characterized by the deposition of monosodium urate (MSU) crystals in joints and soft tissues, resulting from chronic hyperuricemia (serum uric acid > 6.8 mg/dL). Hyperuricemia occurs due to either renal underexcretion of uric acid (90% of cases, often worsened by diuretics, renal insufficiency, or low-dose aspirin) or purine overproduction (10% of cases, seen in myeloproliferative disorders or tumor lysis). MSU crystals precipitate in the joint, phagocytosed by macrophages, which triggers an inflammatory cascade and recruits neutrophils, causing acute synovitis.

Osteoarthritis (OA)

Osteoarthritis is a chronic, progressive joint disorder characterized by the mechanical degeneration of articular cartilage, subchondral bone remodeling, osteophyte formation, and joint space narrowing. It is primarily a degenerative, non-inflammatory disease. Mechanical stress on weight-bearing joints combined with a loss of chondrocyte function leads to cartilage fibrillation, flaking, and erosion. The underlying subchondral bone thickens (subchondral sclerosis) and develops fluid-filled subchondral cysts. Marginally, new bone formation produces bony projections known as osteophytes.

  • Clinical Presentation and Diagnostic Criteria
  • Rheumatoid Arthritis

Joint Distribution: Symmetric polyarthritis primarily affecting the small joints of the hands and feet: metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints, wrists, and metatarsophalangeal (MTP) joints. The distal interphalangeal (DIP) joints and the lumbar/thoracic spine are spared, though the cervical spine can be involved (risk of atlantoaxial subluxation).

Key Symptoms: Morning stiffness lasting greater than 1 hour that improves with physical activity or warm showers.

Deformities: Swan-neck deformity (hyperextension of PIP, flexion of DIP), Boutonniere deformity (flexion of PIP, hyperextension of DIP), and ulnar deviation/drift at the MCP joints.

Extra-articular Signs: Subcutaneous rheumatoid nodules over extensor surfaces, pleural/pericardial effusions, and Felty Syndrome (triad of RA, splenomegaly, and neutropenia).

Diagnostics:

Anti-Cyclic Citrullinated Peptide (Anti-CCP): Most specific marker (>95% specificity).

Rheumatoid Factor (RF): Sensitive but non-specific.

Radiography: Shows symmetric joint space narrowing, periarticular osteopenia, and marginal bone erosions.

Systemic Lupus Erythematosus

Criteria (SOAP BRAIN MD):

  • S erositis (pleuritis, pericarditis)
  • O ral ulcers (painless nasopharyngeal ulcers)
  • A rthritis (non-erosive, involving two or more peripheral joints)
  • P hotosensitivity (skin rash from sun exposure)
  • B lood disorders (hemolytic anemia, leukopenia, lymphopenia, thrombocytopenia)
  • R enal disorder (proteinuria > 0.5 g/day or cellular casts; lupus nephritis)
  • A NA positive (present in >95% of patients; best initial screening test)
  • I mmunologic disorder (anti-dsDNA, anti-Smith, or anti-phospholipid antibodies)
  • N eurologic disorder (seizures or psychosis in the absence of other causes)
  • M alar rash (fixed erythema over the malar eminences, sparing the nasolabial folds)
  • D iscoid rash (erythematous raised patches with adherent keratotic scaling)

Diagnostics:

ANA: Highly sensitive, best initial test.

Anti-dsDNA: Highly specific; titers correlate with disease activity and risk of lupus nephritis.

Anti-Smith (Anti-Sm): Highly specific, but does not correlate with disease activity.

Complement Levels (C3, C4): Decreased during active flares.

Gout

Clinical Signs: Sudden, excruciating onset of warm, erythematous, swollen monoarthritis. The first metatarsophalangeal (MTP) joint is affected in >50% of cases ( podagra ). Chronic gout features tophi (firm deposits of urate crystals) in soft tissues (e.g., Achilles tendon, helix of the ear).

Diagnostics:

Arthrocentesis (Gold Standard): Shows needle-shaped, strongly negatively birefringent crystals (appear yellow when parallel to the polarized light axis).

Radiography: Shows 'rat-bite' punched-out bone erosions with overhanging margins in chronic disease.

Serum Uric Acid: Can be normal during an acute flare.

Osteoarthritis

Clinical Signs: Deep, aching joint pain that worsens with weight-bearing or joint use and is relieved by rest. Morning stiffness is brief, lasting less than 30 minutes . Bony enlargements include Heberden's nodes (at the DIP joints) and Bouchard's nodes (at the PIP joints). Crepitus is felt during range of motion.

Diagnostics:

Radiography: Shows asymmetric joint space narrowing, subchondral sclerosis, osteophytes, and subchondral cysts.

Synovial Fluid: Non-inflammatory (clear fluid, WBC count < 2,000 cells/mcL).

  • Management and Clinical Safety Rules
  • Rheumatoid Arthritis

First-line Therapy: Disease-Modifying Antirheumatic Drugs (DMARDs) should be started immediately. Methotrexate is the non-biologic drug of choice.

Safety Rules: Methotrexate requires regular monitoring of complete blood count (CBC) and liver function tests (LFTs) due to risks of bone marrow suppression and hepatotoxicity. Folic acid (1 mg daily) must be co-prescribed to minimize GI side effects, stomatitis, and cytopenias. It is strictly contraindicated in pregnancy.

Biologic Therapy: TNF-alpha inhibitors (e.g., Adalimumab, Etanercept, Infliximab).

Safety Rules: Must screen for latent Tuberculosis (PPD or QuantiFERON) and Hepatitis B/C prior to initiation to prevent reactivation.

Symptomatic Bridge: NSAIDs or systemic corticosteroids are used briefly for acute flares or as a bridge while waiting for DMARDs to take effect (6-12 weeks).

Systemic Lupus Erythematosus

Mainstay Pharmacotherapy: Hydroxychloroquine is prescribed to all SLE patients to reduce flares and prolong survival.

Safety Rules: Hydroxychloroquine can cause retinal toxicity (macular degeneration). Requires baseline and annual comprehensive ophthalmologic exams.

Flares & Severe Organ Disease: NSAIDs for mild arthritis. Systemic corticosteroids for acute flares. Immunosuppressants (e.g., Mycophenolate Mofetil, Cyclophosphamide) are indicated for lupus nephritis.

Gout

Acute Flare Management: Focuses on reducing inflammation. First-line options include NSAIDs (e.g., Indomethacin, Naproxen), Colchicine (best within 36 hours; side effects include severe diarrhea), or Corticosteroids (oral or intra-articular).

Safety Rules: Avoid NSAIDs and Colchicine in patients with moderate-to-severe Chronic Kidney Disease (CKD) or active peptic ulcer disease; use corticosteroids instead. Do NOT initiate or stop urate-lowering therapy (Allopurinol) during an acute flare, as sudden shifts in uric acid can prolong inflammation.

Chronic Management (Urate-Lowering Therapy): Indicated for patients with >= 2 flares/year, tophi, or uric acid stones. Allopurinol is first-line.

Safety Rules: Co-prescribe low-dose Colchicine or NSAIDs for the first 3-6 months of Allopurinol initiation to prevent mobilization flares. Screen for the HLA-B*5801 allele in patients of Asian or African descent before starting Allopurinol due to a high risk of life-threatening Stevens-Johnson syndrome/hypersensitivity.

Osteoarthritis

Management: Weight loss and low-impact exercise are primary. First-line pharmacotherapy is topical NSAIDs (e.g., Diclofenac gel) for superficial joints (hand, knee), which minimize systemic absorption. Oral NSAIDs (e.g., Ibuprofen, Celecoxib) are used with caution in elderly patients, often co-prescribed with a PPI for gastroprotection. Intra-articular corticosteroid injections provide temporary relief. Surgical joint replacement is the definitive treatment for severe functional impairment.

Comparison Table: Autoimmune & Inflammatory MSK Conditions

Feature Rheumatoid Arthritis (RA) Systemic Lupus (SLE) Gout Osteoarthritis (OA)

Primary Joint Findings Symmetric small joint polyarthritis; spares DIP Non-erosive arthritis, typically transient Acute monoarthritis; podagra (first MTP) Asymmetric weight-bearing; DIP (Heberden's) & PIP (Bouchard's)

Morning Stiffness > 1 hour; improves with activity Variable; mild None, acute sudden flares < 30 minutes; worsens with activity

Diagnostic Marker Anti-CCP (specific); RF (sensitive) ANA (screening); Anti-dsDNA & Anti-Smith (specific) Needle-shaped, negatively birefringent crystals Asymmetric narrowing, osteophytes on X-ray

First-Line Management Dry-eye screening; Methotrexate + Folic acid Sunscreen; Hydroxychloroquine NSAIDs/Colchicine (acute); Allopurinol (chronic) Topical NSAIDs; weight loss; physical therapy

Key Clinical Trap Skip pre-biologic TB screening Neglect baseline/annual eye exams Start allopurinol during acute flare; omit HLA-B*5801 screening Treat with systemic steroids; ignore GI/renal risk of oral NSAIDs